CYCS and osteosarcoma: In another study reported by Jang et al. (2005), they found that fisetin administration to human osteosarcoma (HOS) cells significantly inhibited growth, induced apoptosis, cleavaged PARP, activated the caspase‐8 and Bax, suppressed the Bcl‐2 levels, and released cytochrome c (Jang et al., 2005).